In the Women's Health Initiative, 8,506 women took combination hormone replacement therapy (estrogen and progestin) and were followed for an average of 5.2 years. The women were evaluated for high risk by the Gail Model and were not found to be at increased risk of developing breast cancer. They had yearly mammograms and breast exams during their follow-up visits. However, after long-term therapy, the women on the combination hormone replacement therapy had a 26 percent higher incidence of breast cancer than those taking a placebo. The number of in situ (early stage) breast cancers was not affected. This study was stopped early because of the increased number of breast cancers seen in the estrogen-progestin group. This is consistent with previous studies, which reported an increase in the number of breast cancer cases in women who took the estrogen-progestin combination. However, the Women's Health Initiative revealed that women (with hysterectomies) who took estrogen alone did not show a significant increase in breast cancer risk. The women who stopped their hormones were followed for breast cancer risk and were found to have decreased risk once they stopped their hormones. This risk reduction was seen after 18 months of being off their hormones.
Endometrial cancer is a type of uterine cancer that involves the lining of the uterus. It is seen in women who take estrogen only and still have a uterus. This is due to estrogen's effect on this lining, which builds up with prolonged estrogen stimulation. When this occurs, endometrial hyperplasia can result. This cancer was also monitored in the Women's Health Initiative. The risk of endometrial cancer was not increased by estrogen-progestin therapy in the study. Tamoxifen, an agent that can reduce the risk of developing breast cancer, can also cause endometrial cancer due to its similar effect on the endometrial lining.
In the Women's Health Initiative study, there was a 37 percent decrease in colon cancers in women who had taken hormones compared to women who did not. This was a beneficial effect seen with hormones. The actual mechanism as to how this occurs is not clear.
A study from the Breast Cancer Detection Demonstration Project looked at 329 cases of ovarian cancer to determine whether hormones increase ovarian cancer risk. Results showed that women who took estrogen only were at increased risk of developing ovarian cancer. This risk increased with longer duration of use, especially if taken for 10 or more years. Short-term estrogen-progestin combination therapy did not show an increase in risk.
Hormone replacement therapy and estrogen-dependent cancers have been a controversial issue. The Women's Health Initiative was a large prospective study trying to answer specific questions about hormones and their effects on the body. The results showed a 26 percent increase in breast cancers, no effect on endometrial cancer, and a 37 percent reduction in colon cancers. However, the results have raised additional questions about hormone replacement therapy.
It is important to discuss your risk of developing these cancers with your physician. If you are at increased risk, then long-term hormone replacement therapy may not be the best option for you. Review the risks and benefits of hormone therapy so you can make an informed decision.
© Copyright 1995-2013 The Cleveland Clinic Foundation. All rights reserved.
Can't find the health information you’re looking for?
This information is provided by the Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition. This document was last reviewed on: 8/22/2013…#10312